Tag: Metastatic Urothelial Cancer Therapy 2024

Home / Metastatic Urothelial Cancer Therapy 2024

Categories

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant...
metastatic-urothelial-cancer-therapy-2024

Scan the code